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a one-year follow-up period. DPNP patients aged 18–64 years initiated on duloxetine 
(Dulox) or other standard of care (SOC) therapies, including tricyclic, venlafaxine, 
gabapentin, and pregabalin, between March 1, 2005 and December 31, 2005 were 
selected. Initiation of treatment was deﬁned as no pill coverage over the prior 90 days. 
The ﬁrst observed prescription claim denoted as the “index date”. SOC patients were 
randomly matched (ratio 1:1) to Dulox patients via propensity score matching control-
ling for patient demographics, clinical characteristics, and prior health care utilization. 
Opioid utilization and health care costs were compared between matched study 
cohorts. RESULTS: Propensity score matching resulted in 112 Dulox and 112 SOC 
patients. Compared with SOC patients, Dulox patients were less likely to use any 
DPNP-related opioids (52.7% vs. 82.1%, p  0.01). Patients who initiated duloxetine 
had 2.0 fewer opioids prescription dispensed (p  0.01) and 32 fewer days on opioids 
(p  0.01) than those in the SOC cohort. Patients in the Dulox cohort were initiated 
on opioids approximately four months later than SOC patients (p  0.01). The cumula-
tive opioid dose in morphine equivalents were signiﬁcantly lower for Dulox patients 
than SOC patients (833 mg vs. 3,114 mg, p  0.01). Dulox cohort had signiﬁcantly 
lower total health care costs than SOC cohort ($22,273 vs. $34,785, p  0.05), primar-
ily due to lower outpatient costs ($7,567 vs. $17,584, p  0.01). CONCLUSIONS: 
Duloxetine treatment appears to be associated with delayed use of opioids among 
patients with DPNP. Health care costs were also lower for patients initiated on 
duloxetine vs. SOC treatment.
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OBJECTIVES: From a German health care perspective, to evaluate the cost per patient 
in achieving KDOQITM targets with the use of a combination of cinacalcet  traditional 
therapy (TT). METHODS: The number of patients eligible for cinacalcet was derived 
from the OPen-label, Randomized Study Using Cinacalcet HCL To IMprove Achieve-
ment of KDOQITM Targets in Patients With End-Stage Renal Disease (OPTIMA) Trial 
[1], assessing the efﬁcacy of adding cinacalcet to a TT protocol in controlling bone 
metabolic parameters in dialysis patients with secondary hyperparathyroidism over a 
23-week period. KDOQITM targets considered are: iPTH a300 pg/mL, calcium (Ca)  
9.5 mg/dL and phosphorus (P)  5.5 mg/dL. Resource utilization included the average 
dose per day, average duration of therapy, and cost per dose. The model compares 
the cost per patient who achieves target and the cost per week to maintain target, with 
the use of a combination of cinacalcet  TT relative to TT alone or no therapy. 
RESULTS: At the end of the study period, 30.2% (111) of patients receiving cinacalcet 
 TT achieved their KDOQITM targets, compared with 2.7% (5) for TT. The average 
cost per week of maintaining target was a349.10 for patients on cinacalcet  TT and 
a597.29 for patients on TT. The incremental cost per incremental week in target was 
a491.40 with TT compared with no therapy and was cost-saving (minus 39.68a per 
week) with cinacalcet  TT. The incremental cost per incremental patient at target 
after 23 weeks was a5,895.06 for patients receiving cinacalcet  TT compared with 
TT and a36,991.66 for patients receiving TT compared with no therapy. CONCLU-
SIONS: Patients administered cinacalcet  TT maintain, on average, KDOQITM targets 
longer than patients receiving TT and require less resources. This translates into lower 
costs per patient (compared with TT) to achieve and maintain KDOQITM targets. 1. 
Messa et al. Clin J Am Soc Nephrol. 2008;3:36–45.
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OBJECTIVES: Costing studies often do not identify the excess costs incurred by the 
health care system for patients with a disease vs. patients without the disease. Using 
cohort based cost estimates without controlling for costs also incurred by a non-
disease population can bias projections, long-term modeling and economic evaluation 
analyses. The objective of this study was to estimate the prevalence, total and excess 
costs attributable to diabetes and its complications in Ontario, Canada over 11 years 
(1995 to 2005). METHODS: Newly diagnosed type 1 and 2 diabetes cases aged 35 
and over were identiﬁed from the Ontario Diabetes Database and matched 1:2 using 
propensity scores with controls (non-diabetes cases). The following complications 
were identiﬁed: myocardial infarction, stroke, angina, heart failure, blindness in 1 eye, 
amputation, nephropathy and cataracts. Excess costs of diabetes were estimated as 
the difference between costs attributed to patients with diabetes vs. those attributed 
to patients without diabetes. RESULTS: The prevalence of diabetes rose drastically, 
from 6.5 to 10.5%. Excess costs were $2930 in the year of diabetes diagnosis and 
$1240 in subsequent years. In the year of an event, cost differences were greatest for 
patients with diabetes who had an amputation ($5133), followed closely by nephropa-
thy ($4117) and stroke cases ($3965). Excess costs were apparent for both females 
and males, and the cost amount was strongly associated with increasing age. CON-
CLUSIONS: Results demonstrate that relying on costs from a population with only 
the disease (i.e. diabetes) with no control can overestimate costs of the disease and 
associated complications. Assessing excess costs of disease is important for costing 
studies, longer-term modeling and economic evaluations in general. Existing studies 
which do not account for excess cost may overestimate cost and potentially bias esti-
mates of cost-effectiveness or cost savings due to effective patient management.
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OBJECTIVES: Stakeholders in Europe remain keenly interested in obtaining informa-
tion to help assess country-speciﬁc value of SMBG for patients with type-2 diabetes 
and treated with OADs. From national reimbursement system perspectives in France, 
Germany, and Spain, this study modeled the long-term (40-year) cost-effectiveness of 
SMBG at 1, 2, or 3x/day (vs. no SMBG) for this patient population. METHODS: 
SMBG input costs (strips, lancets, monitors, nurse training) were supplied by LifeScan 
in a2007 values and applied as appropriate for each country’s current reimbursement 
policy. Cohort characteristics and assumed HbA1c effects came from a U.S. Kaiser 
Permanente longitudinal analysis of new SMBG users. Country-speciﬁc complication 
costs obtained from published sources were inﬂated to a2007 values. Base-case out-
comes were discounted at 3% per annum for France and Germany; 6% for Spain. 
Sensitivity analyses varied time horizon (5, 10, 20 years) and discount rates relevant 
to each country. Sensitivity analyses also included a 0.036 dis-utility for SMBG in 
year 1. RESULTS: Incremental cost-effectiveness ratios (ICERs) were largest in France, 
where monitors were included as reimbursed SMBG acquisition costs. ICERs for 
SMBG 1x, 2x, and 3x/day were a12,114, a6,282, and a7,958, respectively. ICERs for 
SMBG 1 or 2x/day were a2,000 in Germany and a4,000 in Spain. ICERs for SMBG 
3x/day were a6000/QALY in both countries. Results were most sensitive to the 5-year 
time horizon. With the SMBG dis-utility, ICERs increased only modestly (a321– 
a2264/QALY) in all scenarios except SMBG 1/day in France, where it increased by 
a9578. CONCLUSIONS: With SMBG cost assumptions reﬂecting current payer reim-
bursement in France, Germany, and Spain, the use of SMBG was found to be cost-
effective. This study adds to the literature on the impact of assuming an SMBG 
dis-utility, and on the country-speciﬁc, long-term value of SMBG as a management 
tool for type-2 diabetes patients treated with OADs.
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OBJECTIVES: Diabetes type 2 is a major health problem with severe complications 
and a signiﬁcant impact on quality of life. International guidelines, developed to 
provide better care and to prevent complications, are difﬁcult to translate into daily 
practice. Especially the lack of prevention of retinopathy and nephropathy through 
frequent screening are a current concern. The aim of this study is to assess the 
minimum impact a program at a pre-speciﬁed policy deﬁned cost, supporting general 
practitioners to put recommendations into daily clinical practice, has to achieve to be 
cost-effective. METHODS: We estimated the minimum number of patients, with a 
mean age of 65 years, that should be screened annually for respectively retinopathy 
and nephropathy, for the program at an implementation cost of a195 per patient, to  
be cost-effective. For both complications, a Markov model, adapted from published 
peer-reviewed models, was developed simulating the evolution of a patients cohort 
with type 2 diabetes over 25 years with cycles of 1 year. A public health care payer 
perspective in a Belgian setting was chosen. Transition probabilities were obtained 
from local epidemiological studies and published trials. Cost data of the different states 
were collected from literature and from the National Institute for Health and Disabil-
ity Insurance. Utility data for all states were obtained from published studies. A ratio 
of a30,000/QALY was used as threshold of willingness to pay for health gain. 
RESULTS: We found for nephropathy a net-saving cost of a6500/QALY when there 
is only an increase in annual screening of 10%. For retinopathy we found a net price 
of a1005 but no health gain. CONCLUSIONS: A scientiﬁc program in a Belgian 
setting with a given implementation cost of a195 per patient and a minimum increase 
in screening in the intervention group, would be cost-effective in the prevention of 
nephropathy and retinopathy.
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OBJECTIVES: The aim of this health economic analysis was to assess the cost-effec-
tiveness of biphasic insulin aspart (BIAsp) when switched from biphasic human insulin 
30 (BHI), based on type 2 diabetes patients from a prospective, multicentre, open 
label, non-controlled, observational, 24-week study. METHODS: A published and 
validated computer CORE Diabetes Model was used to project long-term economic 
and clinical outcomes in sub-cohort of type 2 diabetes patients treated with BIAsp 30 
versus BHI 30. The cohort had 831 (372 male) patients. There was HbA1C decrease 
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from 8.98 o 1.44% to 7.91 o 1.19% , decrease in BMI 0.26 o 1,36 kg/m2 and reduc-
tion in major and minor hypoglycemic events by 97% and 80% respectively. Proba-
bilities of complications, management costs adjustments (including complications) 
were derived from the Czech surveys from 2007. Treatment costs were from June 
2009. Future costs and clinical beneﬁts were discounted at 3.5 % per annum. 
RESULTS: The short-term beneﬁts of switching from BHI 30 to BIAsp 30 are pro-
jected to lead to an increase in discounted quality-adjusted life expectancy of 0.493 
years (4191 o 0.090 versus 3698 o 0.078). Increased total lifetime costs/patient is -
CZK122,594 (534,259 o 1,9925 versus 65,7212 o 21,908) with BIAsp 30. Combining 
costs and clinical outcomes results in an incremental cost-effectiveness per quality-
adjusted life year (QALYs) gained were dominant. CONCLUSIONS: CORE diabetes 
T2 patients sub-cohort simulation in 35 years perspective Czech observational study 
has demonstrated acceptable cost-effectiveness for patients with type 2 diabetes treated 
BIAsp 30. BIAsp 30 treatment was projected to be associated with improvements in 
life expectancy, QALYs and cost saving compared to BHI 30. Sensitivity analyses show 
cost-effectiveness result to be robust.
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OBJECTIVES: Imbalanced levels of parathyroid hormone (PTH), serum calcium (Ca) 
and phosphorus (P) are associated with an increased risk of cardiovascular death and 
fracture. Cinacalcet can regulate these levels in patients with SHPT. Here we describe 
a cost-utility analysis of cinacalcet treatment in SHPT patients in Italy. METHODS: 
We developed a probabilistic patient-level simulation Markov model to simulate the 
effect of cinacalcet on individual Ca, P, and PTH levels (based on data of a European 
multicenter, open-label study); to correlate these levels with mortality and morbidity 
(cardiovascular events, fractures, and parathyroidectomies) recently published in two 
reviews; and to incorporate Italian data for dialysis patients and national cost struc-
ture. Simulation horizon was patient lifetime; simulated treatment alternatives were 
standard treatment (mainly vitamin D sterols and phosphate binders), and cinacalcet 
plus standard treatment. A 3.5% discount rate was applied to life expectancy (LE), 
quality-adjusted life expectancy (QALE), and costs and times in ranges (TiRs) recom-
mended by the KDOQI initiative. Utilities were derived from a prospective cross sec-
tional survey of 180 end-stage renal failure patients with and without co-morbidities. 
Costs were evaluated from the Italian National Healthcare Service perspective. 
RESULTS: Base case results were calculated with 10,000 iterations. Cinacalcet-treated 
patients had a mean (SD) increase in TiR of 5.60 (6.57), 3.45 (6.85), 1.62 (5.64) and 
2.85 (5.60) discounted patient years for PTH, Ca, P, and all parameters, respectively. 
Mean LE extension was 1.16 (3.74) life-years and QALE increase 0.77 (2.63). The 
incremental cost-effectiveness ratio (ICER) calculated considering the TiR varied from 
a5,439 per patient-year in range to a18,748 per patient-year in range (limits for PTH 
and P, respectively). When considering LE, the average ICER results were a26,148/LY 
while when considering QALE, the average ICER was a39,454/quality-adjusted life 
year. CONCLUSIONS: Cinacalcet treatment could be considered cost-effective but 
further investigation is needed.
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OBJECTIVES: To investigate the health economics outcomes of insulin glargine (GLA) 
usage in comparison with insulin NPH (NPH) in diabetes type-2 (DM 2) in real 
practice in the Russian Federation. METHODS: Observational study has been per-
formed in 92 centers in 35 cities of Russia. Two goups of patients (1st- 100 pts received 
GLA o.d, 2d—100 pts—NPH bid) were analized for 6-months period. Group GLA 
had been switched previously from NPH. Efﬁcacy was evaluated according to HbA1ñ 
level as target a7%. The performed CEA analysis included direct costs of medications 
based on average dosages, hospitalizations, days of disability and hypoglycemias. 
RESULTS: The duration of DM 2 was equal in both groups—above 9 years. In 
GLA—87% pts and in 92% NPH pts had high HbA1c at baseline, and 45% and 82% 
(p  0.001) after the end of the study accordingly. Average daily doses of GLA at the 
end of the study were 32.9 UI and for NPH—34,1 UI. Hospitalization rate was higher 
in NPH than in GLA (1,44 vs 0,73 day/patient, p  0.01), disability days (1,37 vs 
0,82 days, p  0.05). The CER was better for GLA vs NPH—a314 RUR and 780 
RUR accordingly. Increase of additional cost was higher for NPH (23.71%) than for 
GLA (7.78%) per patient. CONCLUSIONS: GLA in DM 2 is more cost-effective in 
comparison with NPH due to a better efﬁcacy and safety.
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OBJECTIVES: Type-2 diabetes mellitus (T2DM) is a progressive chronic disease 
placing a huge clinical and ﬁnancial burden on health care services. A recent random-
ized open-label clinical trial (NCT00082381) comparing exenatide with insulin 
glargine provided evidence of the short-term clinical proﬁle of exenatide. The objective 
of this cost-effectiveness analysis was to use these results as the basis for long-term 
projections to estimate the clinical and cost outcomes associated with exenatide treat-
ment versus insulin glargine over a 15-year time horizon in a Turkish setting. 
METHODS: The analysis used the previously published and validated IMS Core 
Diabetes Model, comprised of a series of Markov-based submodels simulating the 
major complications of diabetes (cardiovascular, renal, eye and neurological disease). 
Using baseline characteristics (mean age 58.9 years; 55.7% male; mean HbA1c 8.21%; 
mean duration of diabetes 9.56 years), complications and concomitant medications 
from study NCT00082381, analysis was performed using a non-parametric bootstrap-      
ping approach where disease progression was simulated to estimate costs, life expect-
ancy and quality-adjusted life expectancy (QALE). RESULTS: Exenatide treatment 
was projected to improve life expectancy (mean[SD] years: 8.41[0.09]) and QALE 
(mean[SD] quality-adjusted life years [QALY]: 6.00[0.07]) compared with insulin 
glargine (mean[SD] years: 8.38[0.08]; mean[SD] QALY: 5.62[0.06]), while also delay-
ing the onset of diabetes-related complications (years to onset: exenatide: 4.04; insulin 
glargine: 4.00). Lifetime direct medical costs were higher for exenatide with a 
mean(SD) of 53,573(819) New Turkish Lira (YTL) compared with insulin glargine 
YTL 42,361(770). The incremental cost-effectiveness ratio (ICER) based on QALE 
for exenatide was YTL 30,018 per QALY gained versus insulin glargine. CONCLU-
SIONS: The outcome of this analysis was that exenatide treatment was projected to 
improve life expectancy and QALE and reduce cumulative incidence of most diabetes-
related complications including cardiovascular disease, compared with insulin glargine. 
By current Turkish standards, the ICER for exenatide would be considered to repre-
sent good value for money.
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OBJECTIVES: To estimate the cost-utility of vildagliptin in the treatment of diabetes 
mellitus type 2, in combination with metformin, compared to the standard strategy        
of treatment in Poland: combination of metformin and sulphonylure.       METHODS: 
The cost-utility analysis is based on Markov decision model (package Tree Age Pro        
2008). The following strategies of treatment were compared: vildagliptin (50 mg twice     
daily) versus glimepiride (mean dose 4,5 mg/day) both added to metformin (mean dose            
1892 mg/day). Direct medical costs were considered: cost of oral antidiabetic drugs          
(OAD), cost of insulin, additional costs of treatment of type 2 diabetes (e.g. test strips, 
lancets), cost of general practitioner, cost of specialist visits, cost of complications of         
type 2 diabetes mellitus treatment. Polish cost data was used. The units of effectiveness    
in the analysis were quality adjusted life years (QALY) and life years gained (LYG). 
The outcome of the analysis was incremental cost-effectiveness ratio (ICER), which 
presents the cost of gaining one additional unit of QALY or LYG in the case of using 
therapy with vildagliptin instead of the comparator. Data concerning clinical effective-
ness of compared interventions and also of other strategies of treatment (used after 
OAD treatment) were taken from RCT studies, long term studies and systematic 
reviews. The target population consisted of adult patients with diagnosed diabetes 
mellitus type 2, inadequately controlled with metformin in monotherapy. Both payer’s  
perspective (National Health Fund and patient) and a lifelong time horizon were 
assumed in the analysis. RESULTS: Cost of gaining one additional unit of QALY 
and one additional unit of LYG in the case of using combination therapy 
vildagliptinmetformin instead of therapy glimepiridemetformin is 58,483 PLN and 
589,575 PLN, respectively. CONCLUSIONS: Assuming the Polish acceptable thresh- 
old which is 91,914 PLN, treatment with combination of vildagliptin and metformin           
is cost-effective.
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OBJECTIVES: Diabetic nephropathy is a frequent and serious complication in patients 
with type-2 diabetes mellitus (DM), and it is the most frequent cause of End Stage 
Renal Disease (ESRD) in industrialized countries. The global incidence of ESRD con-
tinues to rise, and ESRD patients requires intensive and costly treatments such as 
dialysis or transplantation; thus, the burden of illness is growing and the resources 
allocated to treatment are increasing. The objective of our study was to evaluate the 
economic impact of losartan added to the standard care administered to diabetic 
subjects with End-Stage Renal Disease in Italy. METHODS: We conducted a cost-
effectiveness analysis comparing the economic and clinical outcomes deriving from the 
administration of additional losartan to standard care versus standard care alone in 
